| # | Title | Journal | Year | Citations |
|---|
| 1 | Pancreatic β‐cell mass in European subjects with type 2 diabetes | Diabetes, Obesity and Metabolism | 2008 | 661 |
| 2 | Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes | Diabetes, Obesity and Metabolism | 2013 | 658 |
| 3 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial | Diabetes, Obesity and Metabolism | 2007 | 601 |
| 4 | Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c | Diabetes, Obesity and Metabolism | 2010 | 584 |
| 5 | Adiponectin - a key adipokine in the metabolic syndrome | Diabetes, Obesity and Metabolism | 2006 | 543 |
| 6 | Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise | Diabetes, Obesity and Metabolism | 2013 | 539 |
| 7 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin | Diabetes, Obesity and Metabolism | 2007 | 479 |
| 8 | Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors | Diabetes, Obesity and Metabolism | 2012 | 479 |
| 9 | Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women | Diabetes, Obesity and Metabolism | 2006 | 461 |
| 10 | Incretin hormones: Their role in health and disease | Diabetes, Obesity and Metabolism | 2018 | 451 |
| 11 | Insulin-associated weight gain in diabetes – causes, effects and coping strategies | Diabetes, Obesity and Metabolism | 2007 | 446 |
| 12 | Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Diabetes, Obesity and Metabolism | 2013 | 432 |
| 13 | Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review | Diabetes, Obesity and Metabolism | 2011 | 428 |
| 14 | Role of vitamin D in the pathogenesis of type 2 diabetes mellitus | Diabetes, Obesity and Metabolism | 2008 | 410 |
| 15 | The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia | Diabetes, Obesity and Metabolism | 2012 | 398 |
| 16 | Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes | Diabetes, Obesity and Metabolism | 2006 | 393 |
| 17 | COVID‐19 infection may cause ketosis and ketoacidosis | Diabetes, Obesity and Metabolism | 2020 | 393 |
| 18 | Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes | Diabetes, Obesity and Metabolism | 2015 | 392 |
| 19 | Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin | Diabetes, Obesity and Metabolism | 2014 | 391 |
| 20 | Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis | Diabetes, Obesity and Metabolism | 2016 | 355 |
| 21 | Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes | Diabetes, Obesity and Metabolism | 2012 | 348 |
| 22 | Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial | Diabetes, Obesity and Metabolism | 2011 | 345 |
| 23 | Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity | Diabetes, Obesity and Metabolism | 2007 | 343 |
| 24 | Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis | Diabetes, Obesity and Metabolism | 2018 | 336 |
| 25 | Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial | Diabetes, Obesity and Metabolism | 2014 | 323 |
| 26 | Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors | Diabetes, Obesity and Metabolism | 2016 | 322 |
| 27 | Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: A systematic review and meta‐analysis | Diabetes, Obesity and Metabolism | 2020 | 320 |
| 28 | Advanced glycation endproducts: what is their relevance to diabetic complications? | Diabetes, Obesity and Metabolism | 2007 | 316 |
| 29 | Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials | Diabetes, Obesity and Metabolism | 2011 | 309 |
| 30 | Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials | Diabetes, Obesity and Metabolism | 2013 | 309 |
| 31 | Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis | Diabetes, Obesity and Metabolism | 2017 | 305 |
| 32 | Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature | Diabetes, Obesity and Metabolism | 2010 | 296 |
| 33 | Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes | Diabetes, Obesity and Metabolism | 2012 | 286 |
| 34 | Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controls | Diabetes, Obesity and Metabolism | 2014 | 286 |
| 35 | Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes | Diabetes, Obesity and Metabolism | 2010 | 284 |
| 36 | The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus | Diabetes, Obesity and Metabolism | 2012 | 283 |
| 37 | An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines | Diabetes, Obesity and Metabolism | 2020 | 278 |
| 38 | Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial | Diabetes, Obesity and Metabolism | 2011 | 274 |
| 39 | Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial | Diabetes, Obesity and Metabolism | 2009 | 272 |
| 40 | Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity | Diabetes, Obesity and Metabolism | 2017 | 271 |
| 41 | Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study | Diabetes, Obesity and Metabolism | 2011 | 266 |
| 42 | Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects | Diabetes, Obesity and Metabolism | 2011 | 265 |
| 43 | GLP‐1 receptor activated insulin secretion from pancreatic β‐cells: mechanism and glucose dependence | Diabetes, Obesity and Metabolism | 2013 | 265 |
| 44 | New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3) | Diabetes, Obesity and Metabolism | 2015 | 265 |
| 45 | Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study | Diabetes, Obesity and Metabolism | 2007 | 263 |
| 46 | Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy | Diabetes, Obesity and Metabolism | 2009 | 258 |
| 47 | Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes | Diabetes, Obesity and Metabolism | 2005 | 255 |
| 48 | Diabetes is an inflammatory disease: evidence from traditional Chinese medicines | Diabetes, Obesity and Metabolism | 2011 | 255 |
| 49 | Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors | Diabetes, Obesity and Metabolism | 2010 | 250 |
| 50 | Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue | Diabetes, Obesity and Metabolism | 2009 | 247 |
